Lynparza (Olaparib) Patent Expiration, LOE Window & CMS Spending
Lynparza (Olaparib) by AstraZeneca: FDA Orange Book core substance LOE 2027-09-08 (last listed 2041-10-25), 0 AB generics, $719.7M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AstraZeneca |
| FDA Application & Pathway | N208558 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2027-09-08 |
| Last Listed Patent or Exclusivity Date | 2041-10-25 |
| Orange Book Patents (*PED Extensions) | 11 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $719.7M |
| 2024 Medicare Part D Spend | $593.9M |
| 2024 Medicaid Spend | $125.7M |
| Reported Wholesale Price Change (CA SB 17) | 8 WAC filings (max 16.6% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.